IMDX Stock — Insight Molecular Diagnostics Inc.: Cash, EV, Pipeline

Share price

$4.00

Market cap

$130.9M

Cash

$17.8M

Enterprise value

$113.1M

Balance sheet

Cash	$17.8M
Debt	$0.0M
Net cash	$17.8M
Enterprise value	$113.1M
Basic shares	32.6M shares
Fully diluted shares	42.6M shares
Fully diluted market cap	$170.5M
Cash per share	$0.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IMDX daily closes…

Loading price history…

Pipeline assets

GraftAssureDx

Stage not disclosed · Active Modality: diagnostic (kitted in vitro diagnostic test)

Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024, to co-develop and commercialize RUO and IVD kitted transplant products; Bio-Rad also an equity investor)

Indications

Kidney transplant (multiple tissue/organ types planned) (Stage not disclosed)

Status note IVD kitted transplant product for clinical use; clinical trial started in 2025 in conjunction with the IVD submission. Kitted tests require FDA marketing authorization (U.S.) and IVDR approval (EU) before clinical use.

GraftAssureIQ

Stage not disclosed · Active Modality: diagnostic (kitted RUO test)

Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)

Indications

Kidney transplant (Stage not disclosed)

Status note RUO kitted transplant test being developed and commercialized under the Bio-Rad collaboration.

GraftAssureCore

Stage not disclosed · Active Modality: diagnostic (kitted transplant test)

Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)

Indications

Kidney transplant (Stage not disclosed)

Status note Named as a current focus of R&D alongside GraftAssureIQ and GraftAssureDx; iMDx depends on the Bio-Rad collaboration for development and commercialization of kitted transplant products.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07551531	Not disclosed	Not yet recruiting	Sponsor	Insight Molecular Diagnostics	—	Kidney Transplant	—
NCT07060716	Not disclosed	Recruiting	Sponsor	Insight Molecular Diagnostics	—	Kidney Transplant Rejection; Cell-free DNA	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Insight Molecular Diagnostics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

IMDX — Insight Molecular Diagnostics Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials